Small Vessel Diseases: Ultra-realistic Microstructure Computational Model to Refine Individual Treatment
- Conditions
- Small Vessel Disease
- Interventions
- Device: MRI
- Registration Number
- NCT06159140
- Lead Sponsor
- University Hospital, Tours
- Brief Summary
Small vessel disease (SVD) accounts for 25% of strokes and is the second most common cause of dementia after Alzheimer's disease. Unlike other causes of stroke, SVD manifests itself years before the stroke by the accumulation of tissue damage. Although heterogeneous, these lesions appear on Magnetic Resonance Imaging (MRI) as white matter hypersignals (WMH). In this context, the ANR SUMMIT project will characterize these lesions in vivo to develop new markers in the early stages of stroke. It is subdivided into 4 work packages, the third one being promoted by CHRU de Tours.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 20
Prior Enrollement in Tours body donation program Age ≥ 82 years Able to remain supine in the MR scanner for acquisition (duration 60-minutes) Affiliation to social security Informed and written consent
Contraindications to body donation, especially infectious disease (VIH, HBV...) Contraindications to MRI
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Healthy subjects MRI MRI and neuropsychological evaluation
- Primary Outcome Measures
Name Time Method In vivo and ex vivo MRI measures data baseline We will compare In vivo data: 20 MR datasets, 20 quantitative SUMMIT maps (predicted microstructure)
Ex vivo data :
* 3 very high-resolution MR datasets and derived quantitative microstructural maps
* 18 brain samples: scanned at 17.2T by the Neurospin partner and processed with the SUMMIT method to obtain high-resolution quantitative microstructural maps
* these 18 samples will be processed to get ground truth histological 3D volumes (Mircen partner).
Maps of the microstructure parameters obtained from MRI (in and ex vivo) and the SUMMIT method will be quantitatively compared to histological data.
This will validate the SUMMIT method at clinical (in vivo) and mesoscopic resolution (ex vivo).
- Secondary Outcome Measures
Name Time Method Scores at neuropsychological evaluation baseline Scores at neuropsychological evaluation
FLAIR and SUMMIT maps (MRI evaluation) baseline In vivo FLAIR and SUMMIT maps.
Trial Locations
- Locations (1)
UHT of Tours
🇫🇷Tours, France